QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels
- Expansion of QIAseq portfolio to Long Read Panels enables high-resolution analysis of complex genomic regions using long-read sequencing
- Supports NGS platforms such as PacBio for applications including structural variants, HLA typing and repeat expansions
- QIAGEN supporting fully integrated workflow from best-in-class sample preparation through to powerful bioinformatics for analysis and interpretation
QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the launch of its new QIAseq xHYB Long Read Panels, a suite of target enrichment solutions designed to unlock long-read sequencing of genomically complex regions.
This new offering strengthens QIAGEN's position as a provider of differentiated solutions for use on any next-generation sequencing (NGS) platforms spanning both short- and long-read technologies.
The new QIAGEN panels are optimized for use with native long-read platforms, including from PacBio (NASDAQ:PACB), and designed to enable researchers to capture a broader spectrum of genomic variation. Applications include HLA typing, repeat expansion analysis, and the detection of structural variants – areas where short-read sequencing have been shown to have challenges.
"This launch is a major milestone in our genomics strategy and reflects our long-term commitment to enabling cutting-edge science," said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. "We are making investments into our portfolio supporting NGS applications to expand the boundaries of what's possible in areas like immune profiling, complex disease genetics and cancer biology. Our goal is to empower researchers with deeper genomic insights, but also to accelerate the translation of discoveries into future clinical applications."
"We are excited to expand our targeted sequencing offerings in partnership with QIAGEN. These new panels launch at a time when we're seeing enthusiastic adoption of our benchtop sequencer, Vega, which leverages the power of HiFi sequencing. With its long reads, exceptional accuracy, and ability to resolve complex genomic regions, HiFi is unlocking new possibilities in targeted sequencing—especially in clinical and translational research applications," said David Miller, Vice President, Global Marketing, at PacBio.
Built on QIAGEN's proven hybrid-capture chemistry, the QIAseq xHYB Long Read Panels deliver:
- High target completeness and uniformity
- Flexible panel formats – including fixed panels for hereditary cancers and HLA typing, as well as customizable panels
- Compatibility with high-molecular-weight DNA extraction kits
- Seamless integration with QIAGEN Digital Insights bioinformatics for streamlined data interpretation
The launch comes as long-read sequencing gains momentum in areas such as translational and clinical research. Unlike synthetic long-read or short-read technologies, native long-read sequencing provides greater insight into complex genomic regions designed to improve accuracy in haplotype phasing, repeat detection and variant resolution.
QIAGEN's expanded portfolio now allows researchers to choose between short- and long-read sequencing – or combine them – depending on their sample type and research objectives.
QIAGEN's end-to-end NGS solutions empower genomic discovery across research and clinical settings. The portfolio integrates robust extraction kits and instruments for diverse and challenging sample types with dedicated target enrichment panels and streamlined library preparation and quality control automation. These solutions support whole genome, transcriptome, exome, targeted and RNA sequencing, and are compatible with major sequencing platforms. Following sequencing, advanced bioinformatics tools translate complex NGS data into actionable biological insights, enabling applications in academic research, biopharma and oncology.
To learn more about QIAseq xHYB Long Read Panels, visit www.qiagen.com/qiaseq-long-read-seq.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of March 31, 2025, QIAGEN employed approximately 5,700 people in over 35 locations worldwide. For more information, visit www.qiagen.com.
Forward-Looking Statement
Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and / or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results - such as expected adjusted net sales and adjusted diluted earnings - are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, regulatory processes and logistical dependencies), variability in operating results, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated benefits from restructuring programs and acquisitions will materialize as expected. For a comprehensive overview of risks, please refer to the "Risk Factors" contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission.
Source: QIAGEN N.V.
Category: PCR & Genomics
View source version on businesswire.com: https://www.businesswire.com/news/home/20250722620965/en/
Contact QIAGEN
Investor Relations
e-mail: [email protected]
Public Relations
e-mail: [email protected]